Jacobs Levy Equity Management’s Pliant Therapeutics PLRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$733K	Sell	643,120 -75,423	-10%	-$91.8K	﹤0.01%	769
2026 Q1	$905K	Buy	718,543 +161,605	+29%	+$204K	﹤0.01%	727
2025 Q4	$679K	Buy	556,938 +189,825	+52%	+$285K	﹤0.01%	751
2025 Q3	$543K	Buy	+367,113	New	+$560K	﹤0.01%	808
2022 Q1	–	Sell	-14,543	Closed	-$196K	–	1067
2021 Q4	$196K	Buy	+14,543	New	+$231K	﹤0.01%	940

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Jacobs Levy Equity Management's PLRX Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Pliant Therapeutics (PLRX) stake by 10% in Q2 2026, selling an estimated $91.8K and leaving 643,120 shares worth $733K. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Jacobs Levy Equity Management first reported a position in PLRX in Q4 2021 and has held it in 5 quarters since. The position peaked at $905K in Q1 2026. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Jacobs Levy Equity Management held 643,120 shares of Pliant Therapeutics worth $733K as of Q2 2026.
Jacobs Levy Equity Management sold 75,423 Pliant Therapeutics shares in Q2 2026, an estimated $91.8K.
Pliant Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #769 holding.
Jacobs Levy Equity Management first reported a position in Pliant Therapeutics in Q4 2021 and has held it in 5 quarters since.
Jacobs Levy Equity Management's Pliant Therapeutics position peaked at $905K in Q1 2026.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.